×

Indications

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal Read More

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral, and hip fractures.

Prolia® is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Prolia® also reduced the incidence of vertebral fractures.

Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Close

For treatment to increase bone mass in men with osteoporosis at high risk for fracture


With 1 dose every 6 months, Prolia® follows your male osteoporosis patients all year long.

  • 60 mg subcutaneous injection in the upper arm, upper thigh, or abdomen by a healthcare professional
  • Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia®. Adequately supplement all patients with calcium and vitamin D
  • Multiple vertebral fractures have been reported following Prolia® discontinuation
RISK EVALUATION AND MITIGATION STRATEGY (REMS)

Learn about coverage and multiple fulfillment solutions available for your Prolia® patients.

?

Are your patients losing height?

Learn about height loss as one of the many risk factors to look for when considering your male patients at high risk for osteoporosis-related fracture.

  • This image is for illustration purposes only.
Identifying Patients

Prolia® (denosumab) safety profile.

Learn about the Prolia® Risk Evaluation and Mitigation Strategy Program.

REMS

Learn about Prolia® Important Safety Information.

Important Safety Information
Prolia® is
1 Shot Every
6
Months2

Single-use
prefilled 1 mL syringe

  • 60 mg subcutaneous injection in the upper arm, upper thigh, or abdomen by a healthcare professional
  • Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia®. Adequately supplement all patients with calcium and vitamin D
  • Multiple vertebral fractures have been reported following Prolia® discontinuation
  • As a subcutaneous injection, Prolia® does not undergo first-pass metabolism4
  • May lessen patient pill burden
Dosing

Important Safety Information

Following discontinuation of Prolia® treatment, fracture risk increases, including the risk of multiple vertebral fractures. Evaluate an individual’s benefit/risk before initiating treatment with Prolia®. If Prolia® treatment is discontinued, consider transitioning to an alternative antiresorptive therapy.

Prolia® has confirmed medical benefit coverage nationwide.5

You can administer Prolia® in your office or refer your patient to an injection center.

Help your
patients get
Prolia®